Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both Smad and p38 pathways

Journal of Cellular Biochemistry

Volumn 103, Issue 5, 2008, Pages 1584-1597

  Du, Jun ^a   Yang, Shuang ^a   Wang, Zhaoqi ^a   Zhai, Chunli ^a   Yuan, Wei ^a   Lei, Rongyue ^a   Zhang, Jie ^a   Zhu, Tianhui ^a  

^a NANKAI UNIVERSITY   (China)

Author keywords

Apoptosis; BMP6; Breast cancer; p38; Proliferation; Survivin

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; CASPASE 3; ESTROGEN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; SMAD PROTEIN; SURVIVIN;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STARVATION;

APOPTOSIS; BONE MORPHOGENETIC PROTEINS; BREAST NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; FEMALE; G0 PHASE; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, MESSENGER; SMAD PROTEINS; TIME FACTORS;

EID: 41749097417     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21547     Document Type: Article

References (48)

1. Adams JM, Cory S. 1998. The bcl-2 protein family: Arbiters of cell survival. Science 281:1322-1326.
2. Akiyoshi T, Uchida K, Tateyama S. 2004. Expression of bone morphogenetic protein-6 and bone morphogenetic protein receptors in myoepithelial cells of canine mammary gland tumors. Vet Pathol 41:154-163.
3. Altieri DC. 2003. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46-54.
4. Ambrosini G, Adida C, Altieri DC. 1997. A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921.
5. Arnold SF, Tims E, McGrath BE. 1999. Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: Importance of BMP2. Cytokine 11(12):1031-1037.
6. Bitgood MJ, Mcmahon AP. 1995. Hedgehog and Bmp genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. Develop Biol 172:126-138.
7. Celeste AJ, Iannazzi JA, Taylor RC. 1990. Identification of transforming growth factor h family members present in bone-inductive protein purified from bovine bone. Proc Natl Acad Sci USA 87:9843-9847.
8. Chen D, Zhao M, Harris SE, Mi Z. 2004. Signal transduction and biological functions of bone morphogenetic proteins. Front Biosci 9:349-358.
9. Cicek M, Oursler MJ. 2006. Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev 25(4):635-644.
10. Clement JH, Sanger J, Hoffken K. 1999. Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor. Int J Cancer 80:250-256.
11. Coleman RE. 1997. Skeletal complications of malignancy. Cancer 80:1588-1594.
12. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. 2005. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 65:8274-8285.
13. Derynck R, Zhang YE. 2003. Smad-dependent and smad-independent pathways in TGF-beta family signalling. Nature 425:577-584.
14. Drozdoff V, Wall NA, Pledger WJ. 1994. Expression and growth inhibitory effect of decapentaplegic Vg-related protein 6: Evidence for a regulatory role in keratinocyte differentiation. Proc Natl Acad Sci 91:5528-5532.
15. Ducy P, Karsenty G. 2000. The family of bone morphogenetic proteins. Kidney Int 57:2207-2214.
16. Ghosh-Choudhury N, Ghosh-Choudhury G, Celeste A, Ghosh PM, Moyer M, Abboudb SL, Kreisberg J. 2000a. Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim Biophys Acta 1497(2):186-196.
17. Ghosh-Choudhury N, Woodruff K, Qi W, Celeste A, Abboud SL, Ghosh-Choudhury G. 2000b. Bone morphogenetic protein-2 blocks MDA MB 231 human breast cancer cell proliferation by inhibiting cyclin-dependent kinase-mediated retinoblastoma protein phosphorylation. Biochem Biophys Res Commun 272(3):705-711.
18. Gosselet FP, Magnaldo T, Culerrier RM, Sarasin A, Ehrhart JC. 2007. BMP2 and BMP6 control p57(Kip2) expression and cell growth arrest/terminal differentiation in normal primary human epidermal keratinocytes. Cell Signal 19(4):731-739.
19. Hatakeyama S, Gao YH, Nemoto YO, Kataoka H, Satoh M. 1997. Expression of bone morphogenetic proteins of human neoplastic epithelial cells. Biochem Mol Biol Int 42:497-505.
20. Haudenschild DR, Palmer SM, Moseley TA, You Z, Reddi AH. 2004. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 64(22):8276-8284.
21. Hogan BLM. 1996. Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev 10:1580-1594.
22. Javelaud D, Mauviel A. 2005. Crosstalk mechanisms between the mitogen-activated protein kinase pathways and Smad signaling downstream of TGF-b: Implications for carcinogenesis. Oncogene 24:5742-5750.
23. Jones CM, Lyons KM, Hogan BLM. 1991. Involvement of bone morphogenetic protein-4 (BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the mouse. Development 111:531-542.
24. Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP Jr, Ross JS. 2004. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 128:39-43.
25. Kersten C, Sivertsen EA, Hystad ME, Forfang L, Smeland EB, Myklebust JH. 2005. BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1. BMC Immunol 6(1):9.
26. Knittel T, Fellmer P, Muller L, Ramadori G. 1997. Bone morphogenetic protein-6 is expressed in nonparenchymal liver cells and upregulated by transforming growth factor-b1. Exp Cell Res 232:263-269.
27. Kusanagi K, Inoue H, Ishidou Y, Mishima HK, Kawabata M, Miyazono K. 2000. Characterization of a bone morphogenetic proteinresponsive Smad-binding element. Mol Biol Cell 11:555-565.
28. Lennmyr F, Ericsson A, Gerwins P, Ahlstrom H, Terent A. 2003. Increased brain injury and vascular leakage after pretreatment with p38-inhibitor SB203580 in transient ischemia. Acta Neurol Scand 108:339-345.
29. Li F. 2003. Survivin study: What is the next wave? J Cell Physiol 197:8-29.
30. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC. 1998. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396(6711):580-584.
31. Liu F, Hata A, Baker JC, Doody J, Carcamo J, Harland RM, Massague J. 1996. A human Mad protein acting as a BMP-regulated transcriptional activator. Nature 381:620-623.
32. Lories RJ, Derese I, Ceuppens JL, Luyten FP. 2003. Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by proinflammatory cytokines and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum 48:2807-2818.
33. Massague J. 1998. TGF-beta signal transduction. Annu Rev Biochem 67:753-791.
34. Nishimura M, Sugino T, Nozaki K, Takagi Y, Hattori I, Hayashi J, Hashimoto N, Moriguchi T, Nishida E. 2003. Activation of p38 kinase in the gerbil hippocampus showing ischemic tolerance. J Cereb Blood Flow Metab 23:1052-1059.
35. Parkin DM, Pisani P, Fertay J. 1999. GLobal cancer statistics. CA Cancer J Clin 49:33-64.
36. Pluijm G, Lowik C, Papapoulos S. 2000. Tumour progression and angiogenesis in bone metastasis from breast cancer: New approaches to an old problem. Cancer Treat Rev 26:11-27.
37. Rosen LS, Gordon D, Kaminski M. 2003. Long-term efficacy and safety of zotedronic acid compared with pamidronate disodium in the treatment of skeLetaL complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, mutticenter, comparative trial. Cancer 98:1735-1744.
38. Schimmer AD. 2004. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res 64:7183-7190.
39. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T. 1998. LAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, caspases, and anti-cancer drugs. Cancer Res 58:5315-5320.
40. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. 2000. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6(1):127-134.
41. Tateyama S, Uchida K, Hidaka T, Hirao M, Yamaguchi R. 2001. Expression of bone morphogenetic protein-6 (BMP-6) in myoepithelial cells in canine mammary gland tumors. Vet Pathol 38(6):703-709.
42. Ten Dijke P, Korchynskyi O, Valdimarsdottir G, Goumans MJ. 2003. Controlling cell fate by bone morphogenetic protein receptors. Mol Cell Endocrinol 211(1-2):105-113.
43. Urist MR. 1965. Bone: Formation by autoinduction. Science 150:893-899.
44. Waite KA, Eng C. 2003. From developmental disorder to heritable cancer: It's all in the BMP/TGF-beta family. Nat Rev Genet 4:763-773.
45. Wakefield LM, Piek E, Bottinger EP. 2001. TGF-beta signaling in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 6(1):67-82.
46. Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW, Hewick RM, Wang EA. 1988. Novel regulators of bone formation: Molecular clones and activities. Science 242:1528-1534.
47. Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P. 2005. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 65:5769-5777.
48. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. 2002. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. JPET 303(1):124-131.